Olopatadine

Results: 28



#Item
1HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PAZEO* safely and effectively. See full prescribing information for PAZEO. PAZEO (olopatadine hydrochloride ophthalm

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PAZEO* safely and effectively. See full prescribing information for PAZEO. PAZEO (olopatadine hydrochloride ophthalm

Add to Reading List

Source URL: ecatalog.alcon.com

Language: English - Date: 2016-04-27 08:32:13
2HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PAZEO* safely and effectively. See full prescribing information for PAZEO. PAZEO (olopatadine hydrochloride ophthalm

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PAZEO* safely and effectively. See full prescribing information for PAZEO. PAZEO (olopatadine hydrochloride ophthalm

Add to Reading List

Source URL: ecatalog.alcon.com

Language: English - Date: 2016-04-27 08:32:13
3DESCRIPTION PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is a sterile ophthalmic solution containing olopatadine, a relatively selective H1 -receptor antagonist and inhibitor of histamine release from t

DESCRIPTION PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is a sterile ophthalmic solution containing olopatadine, a relatively selective H1 -receptor antagonist and inhibitor of histamine release from t

Add to Reading List

Source URL: ecatalog.alcon.com

Language: English - Date: 2014-08-21 17:11:39
4Division: Pharmacy Services  Subject: Prior Authorization Criteria Original Development Date: Original Effective Date:

Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date:

Add to Reading List

Source URL: ahca.myflorida.com

Language: English - Date: 2012-09-25 12:12:06
5CPDO Examination - Minicase 1 Patient findings: A 27-year-old female presents after an airbag injury to her right eye the previous day. Examination reveals a relative afferent pupillary defect and light-perception vision

CPDO Examination - Minicase 1 Patient findings: A 27-year-old female presents after an airbag injury to her right eye the previous day. Examination reveals a relative afferent pupillary defect and light-perception vision

Add to Reading List

Source URL: www.optometry.org

Language: English - Date: 2013-12-13 16:53:06
6These highlights do not include all the information needed to use PATANASE® Nasal Spray safely and effectively. See full prescribing information for PATANASE Nasal Spray. PATANASE (olopatadine hydrochloride) Nasal Spray

These highlights do not include all the information needed to use PATANASE® Nasal Spray safely and effectively. See full prescribing information for PATANASE Nasal Spray. PATANASE (olopatadine hydrochloride) Nasal Spray

Add to Reading List

Source URL: ecatalog.alcon.com

Language: English - Date: 2014-08-21 13:04:53
722134 Alcaftadine Clinical PREA

22134 Alcaftadine Clinical PREA

Add to Reading List

Source URL: www.fda.gov

Language: English
8Division: Pharmacy Services  Subject: Prior Authorization Criteria Original Development Date: Original Effective Date:

Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date:

Add to Reading List

Source URL: www.ahca.myflorida.com

Language: English - Date: 2012-09-25 12:12:06
9Sterne Kessler Goldstein Fox  Patrick E Larren

Sterne Kessler Goldstein Fox Patrick E Larren

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2006-06-14 10:03:53
10Sports and Fitness Options Open Up

Sports and Fitness Options Open Up

Add to Reading List

Source URL: www.kennedykrieger.org

Language: English - Date: 2013-12-31 08:49:32